AI 制药公司 Pathos 完成 2.37 亿美元 E 轮融资，估值约 30 亿美元
摘要
AI 制药公司 Pathos 宣布完成由 Bristol Myers Squibb 领投的 2.37 亿美元 E 轮融资，估值约 30 亿美元。公司同时从肿瘤领域扩展至神经系统疾病，采用 Tempus AI 的新数据集，并与 BMS 合作优先聚焦阿尔茨海默病治疗。其自研模型 Foundry 运行数千个智能体，评估临床资产的成功概率，用于指导药物选择、受试人群和临床试验设计。
摘要由模型根据原文撰写，以原文为准。
正文 · 原文
Pathos, an artificial intelligence-driven drug development company, announced on Friday it is raising $237 million in a Series E fundraising round led by Bristol Myers Squibb. The deal brings Pathos’ valuation to approximately $3 billion.
Pathos is also expanding from oncology to neurological conditions with new datasets from Tempus AI and a partnership with BMS that will first focus on Alzheimer’s treatments.
Most drugs that enter clinical trials never reach patients, but Pathos’ pitch is that AI can improve the odds. Its proprietary model, Foundry, operates thousands of agents that calculate the probability of success for its clinical assets. The agents analyze clinical data, genomics, biological specimen data, and competition from other developers. This information guides Pathos’s decision-making on which drugs to pursue, what populations to test them in, and how to design the clinical trials.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
注意转载授权 · 阅读原文
来源：STAT News · statnews.com
引用原文
Katherine MacPhail. STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion[EB/OL]. (2026-10-23)[访问日期]. https://www.statnews.com/2026/10/23/pathos-ai-bristol-myers-squibb-tempus-deal/?utm_campaign=rss.